GLP-1-based therapies, such as GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors, improve glucose control through various mechanisms including increased insulin secretion, slower gastric emptying, and reduced postprandial glucagon and food intake
However, contact PlexusDx immediately if you experience spreading redness, significant swelling that persists for more than 24 hours, warmth or drainage from the injection site, or signs of infection such as increasing pain or pus
What "Research Use Only" Actually Means "Research use only" is a regulatory and labeling designation, not a marketing description
Pharmacol Res (2018) 130:13242
Across the SURPASS clinical trials, researchers categorized injection site reactions into several distinct presentations
Sounds like a success story, right